NCT03047213 2026-03-18
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT03898180 2026-02-05
LEAP-011
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
NCT04018053 2026-01-27
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT03473743 2025-12-23
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting